Glaxo: FDA OKs Advair 250/50 to reduce exacerbations in COPD patients – Interactive Investor
Glaxo: FDA OKs Advair 250/50 to reduce exacerbations in COPD patients Interactive Investor, UK - Apr 30, 2008 COPD is a progressive, life-threatening lung disease that includes chronic bronchitis, emphysema or both. With this approval, Advair becomes the only ... |